Abstract
Background With the introduction of effective antiretroviral therapy (ART), descriptions of body shape abnormalities, such as central fat accumulation and peripheral fat loss emerged among persons living with human immunodeficiency virus (HIV). We aimed to determine the prevalence of lipodystrophy and associated risk factors among patients on ART at Orotta National Referral Hospital (ONRH), Asmara, Eritrea.
Methods A single center, retrospective study was conducted at the ONRH, reviewing records of HIV-infected patients commenced on ART between January 2007 and December 2012.
Results Records of 250 eligible patients were reviewed. Most were female (59.2%, n=148) with a median age of 35 (IQR-20-63) years. Forty-three (17.2%) participants had body fat abnormalities. 42 (97.6%) had lipoatrophy and 1 (2.4%) buffalo hump. Of the 43 patients with lipodystrophy 34 (79%) were on Stavudine (d4T)/Lamivudine (3TC)/Nevirapine (NVP) regimen, 6 (14%) on Zidovudine (AZT)/3TC/NVP, 2 (4.7%) on d4T/3TC/Efavirenz (EFV) and 1(2.3%) on AZT, 3TC, EFV. EFV-based regimen was significantly associated with lipodystrophy (p< 0.01).
Conclusion We report a high prevalence of lipodystrophy. Four drug regimens were incriminated in the development of lipodystrophy. EFV-based regimen was significantly associated with the lipodystrophy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. Orotta school of medicine 2. the Research ethics and Protocol review committee of the Eritrean ministry of health
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Addresses: Senai Goitom Sereke: nayhersen{at}gmail.com
Semhar Eyob Berhe: semhareyobmd{at}gmail.com
Felix Bongomin: drbongomin{at}gmail.com
Data Availability
The information used and/or analyzed during this manuscript is available from the corresponding author on reasonable request.
Abbreviations
- 3TC
- Lamivudine
- AIDS
- Acquired Immunodeficiency Syndrome.
- ABC
- Abacavir
- ART
- Antiretroviral Therapy/ Treatment
- Atv/r
- Atazanvir/ritonavir
- AZT
- Zidovudine
- BMI
- Body Mass Index
- CT
- Computed Tomography
- DEXA
- Dual-Energy X-ray Absorptiometry
- d4T
- Stavudine
- ddI
- Didanosine
- EFV
- Efavirenz
- ELISA
- Enzyme-Linked ImmunoSorbent Assay.
- FTC
- Emtricitabine
- HIV
- Human Immunodeficiency Virus.
- HAART
- Highly Active Antiretroviral Therapy/ Treatment
- LPV/r
- Lopinavir/ritonavir
- MoH
- Ministry of Health
- MACS
- Multicenter AIDS Cohort Study
- MRI
- Magnetic Resonance Imaging.
- NVP
- Nevirapine
- NRTIs
- Nucleoside or nucleotide Reverse Transcriptase Inhibitor
- NNRTI
- Non-Nucleoside Reverse Transcriptase Inhibitor
- PI
- Protease Inhibitor
- SJS
- Stevens-Johnson Syndrome
- WHO
- world health organization
